What is AKTS's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 1.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for AKTS?

P/E (TTM) is n/a and 52-week range is $14.72 to $34.19 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s AKTS figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for AKTS?

The company profile lists revenue (TTM) near $13M, net income (TTM) near $-10.25B, EPS (TTM) near $-2.07 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Aktis Oncology Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Boston, Massachusetts, US, 53.4M shares outstanding, ISIN US01021M1045 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Aktis Oncology Inc

$AKTS

Health Care · Biotechnology

Run Scenarios

$18.15

+2.31%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company is headquartered in Boston, Massachusetts and currently employs 79 full-time employees. The company went IPO on 2026-01-09. The firm is focused on expanding the potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The Company’s proprietary mini-protein radio conjugate platform aims to safely confer efficacy to a range of patient populations. Its mini-protein radio conjugates are designed to selectively deliver the tumor-killing properties of radioisotopes to targeted tumors with high tumor penetration and prolonged retention, while being rapidly cleared from normal organs and tissues to minimize systemic radiation exposure. Its pipeline includes AKY-1189 and AKY-2519. AKY-1189, is targeting Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, colorectal cancer and cervical cancer. AKY-2519 targets B7-H3 expressing solid tumors, such as prostate, lung and breast cancers.

Employees

Website

www.aktisoncology.com/

IPO

2026-01-09

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)